Investing in the future of medicine
Bringing science to patients:
We have helped bring
37 products to market.
Bringing science to patients:
We have helped bring
37 products to market.
Omega Funds is a leading international investment firm that creates and invests in life sciences companies that target the world’s most urgent medical needs.
We aim to invest in exceptional founders and entrepreneurs and impactful products and platforms across multiple therapeutic areas, including oncology, immunology, rare diseases, precision medicine and others.
Richard joined Omega Funds in 2008. His career spans 25 years in private equity investing and strategic consulting, all within life science and healthcare. At Omega, he is a member of the firm’s investment committee and acts as President of Omega Fund Management LLC; his primary investment focus is in drug discovery and development companies, and is actively involved in the firm’s secondary buyout practice and investments in academic spinouts.
Previously, Richard was a General Partner at MVM Life Science Partners, a life science-focused venture capital firm, where he founded the firm’s US investment operations. He was previously a Vice President at Saunders, Karp & Megrue (SKM), where he specialized in healthcare growth capital and leveraged buyout transactions. Prior to SKM, now known as Apax Partners Inc., Richard was a Manager at LEK Consulting, providing strategic advice to life science companies; he consulted for more than three dozen small and large biotechnology firms. He was also an Associate with the M&A investment bank BT Wolfensohn. He has served on a number of boards of biotechnology, specialty pharmaceutical, and medical device companies. He serves on the advisory boards of the Deshpande Center at the Massachusetts Institute of Technology. Richard earned his AB and MBA degrees from Harvard University.
Claudio joined Omega Funds in 2016. In addition to managing NeoMed’s funds, Claudio assists with and advises on new investments for Omega and sits on the investment committee.
Claudio joined NeoMed in 2001 and became a Partner in 2004. He has over 15 years’ experience of venture capital investing in healthcare in Europe and the US. Prior to NeoMed, Claudio was a Venture Partner with Genevest Consulting Group SA, Geneva. He has academic research experience in molecular biology from the Max Planck Institute and the University of Connecticut. Claudio has an MBA from Erasmus University, the Netherlands and a PhD degree in Genetics from the University of Pavia, Italy.
Anne-Mari joined Omega Funds in 2009 after 17 years in healthcare venture capital finance. At Omega, Anne-Mari is a member of the Investment Committee and is responsible for overseeing the firm’s financial and administrative operations.
Previously, she was a Partner and Chief Financial Officer at Third Rock Ventures (TRV), a venture firm focused on life sciences investing. She joined TRV to establish its operations and assisted the firm in successfully raising its inaugural fund in 2007. She managed all fund, company and portfolio operations as well as investor relations. Prior to TRV, Anne-Mari served as CFO of MPM Capital, a leading biotech venture capital firm with 4 funds and over $2.3 billion under management. During her 14-year tenure with MPM, she was responsible for financial management of MPM’s venture funds and other entities, financial reporting, building and oversight of all back office operations, investor relations and office administration. She was also a Founder and CFO of APS Material Services. Anne-Mari received her BS in Engineering at the Turku Institute of Technology in Finland and has completed advanced studies in corporate finance at Boston University.
Otello founded Omega Funds in 2004 and leads the firm’s investor relations and strategic initiatives. He is a member of the firm’s investment committee and is also heavily involved in a number of Omega’s therapeutic areas of interest, particularly in oncology, rare diseases and inflammatory disorders.
Previously, Otello was in charge of life sciences direct investments and diligence for healthcare venture fund of fund investments at AlpInvest Partners, one of the largest private equity asset managers worldwide. Before AlpInvest, he was the portfolio manager of the Lombard Odier Immunology Fund, a $3 billion listed investment vehicle in Geneva, Switzerland, investing in public and private healthcare companies worldwide. Previously, Otello was a member of the HealthCare corporate finance and M&A team at Goldman Sachs (London and New York offices). Before Goldman, he helped co-found the healthcare investment activities at Index Securities (now Index Ventures). Otello has a PhD in Molecular Biology from the University of Geneva, holds a European Doctorate in Biotechnology from the EU, and obtained an MSc in Genetics from the University of Pavia.
Dina joined NeoMed in 2009. She manages NeoMed’s funds and assists with and advises on new investments for Omega. Dina has been investing in the private equity and venture capital healthcare industry since 2001. Previously at 3i in London and Index Ventures in Geneva, her recent investments including Attenua, Imago BioSciences, Oxular, TopiVert, Wilson Therapeutics, EUSA Pharma, Endosense and Novexel.
Dina is a member of the Venture Capital Platform Council of Invest Europe. She is a CFA charterholder and holds a Ph.D. degree in Molecular and Cellular Biology from Paris VI University, France and carried out postdoctoral research at Brown University, Providence, US, and at the Fox Chase Cancer Centre, Philadelphia, US.
Michelle joined Omega Funds in 2016. She has nearly 20 years of experience advising life sciences companies on private placements, public equity financing and M&A transactions. Previously, Michelle worked as Director of Corporate Finance at Third Rock Ventures, where she supported numerous portfolio companies. Prior to joining Third Rock, Michelle was Principal, Corporate Finance, at Abingworth. She was also a life sciences investment banker with Lehman Brothers International in London, JP Morgan/H&Q in New York and Morgan Stanley in Toronto and New York. Michelle has executed more than 40 equity and convertible transactions and numerous IPOs, private placements and M&A transactions for companies, including Gilead, MedImmune, Millennium, Illumina and Sepracor. Michelle graduated with an Honor’s degree in Business Administration from the Richard Ivey School of Business at the University of Western Ontario in London.
Francesco rejoined Omega Funds in 2016, where he focuses on private company investing. He is also heavily involved with Omega’s direct secondary transactions and investor relations.
Prior to joining Omega, Francesco was an Analyst at Brookside Mezzanine Partners, a $500 million mezzanine fund investing in subordinated debt and minority equity in small- to mid-size companies throughout the U.S., where he focused on due diligence, deal management, and investor relations. Concurrently, he worked for uConnect, a SaaS education technology start-up helping university career centers impact student outcomes, where he focused on fundraising, finance, and operations. Prior to Brookside and uConnect, Francesco was an Associate at Commonfund Capital (CCI), the private capital arm of the $24 billion fund of funds Commonfund, where he focused on due diligence, manager selection, investment management, and investor relations for CCI’s private equity, venture capital, and natural resources programs. He began his career at Omega, when he joined in 2008, as an Analyst. Francesco graduated cum laude from the Isenberg School of Management at the University of Massachusetts Amherst with a BBA in Finance and Operations Management. He is also a CFA charterholder, a CAIA charterholder, and a Certified FRM.
Thomas joined NeoMed in 2005. He manages NeoMed’s funds and assists with and advises on new investments for Omega.
Thomas has over 10 years of experience of venture capital investing in healthcare in Europe. Previously, he was a global biotechnology analyst for Pictet & Cie, Switzerland’s largest private bank. He was also Manager of Regulatory Affairs with worldwide responsibilities at Firmenich SA, a global leader in fragrances, flavourings and fine chemicals. Thomas holds a PhD in molecular biology from the University of Geneva, Switzerland.
Paulina joined Omega Funds in 2019. Prior to joining Omega, Paulina was on the healthcare team at Polaris Partners since 2012. Paulina is currently an observer on the board of Arrakis Therapeutics. Paulina previously served on the boards of Kala Pharmaceuticals (NASDAQ: KALA), Neuronetics (NASDAQ: STIM), Lyra Pharmaceuticals, Faraday Pharmaceuticals, Arsenal Medical and CAMP4 Therapeutics, where she was the founding CEO. Paulina completed her postdoctoral fellowship in Robert Langer’s lab in the Chemical Engineering department at the Massachusetts Institute of Technology. Paulina was the founding president of the MIT Postdoctoral Association and served on the MIT Intellectual Property Presidential Committee. Paulina completed her PhD in Molecular Medicine from the Wake Forest University School of Medicine and graduated magna cum laude from East Carolina University with a quadruple major in biochemistry, neuroscience, biology and chemistry.
Katie joined Omega Funds in 2019. She focuses on Omega’s investor relations, including marketing and fundraising, and is also involved in the monitoring of existing public company investments.
Prior to joining Omega, Katie spent five years in equity research covering specialty pharmaceutical companies, initially as an Associate at BMO Capital Markets in New York and most recently as a Vice President at Wells Fargo Securities in New York. Katie also has an extensive journalism background, including on-air roles with an NBC-affiliate local news station and a national online news network, along with reporting/producing positions with CNBC and Bloomberg, in New York and London. Katie graduated cum laude from the School of Journalism at the University of Missouri with a Bachelor of Journalism degree. She also maintains FINRA Series 7, 63, 79, 86, and 87 licenses and is a CFA Level III Exam Candidate.
Annie joined Omega Funds in 2015. She focuses on private company investing, particularly in the areas of oncology, autoimmune and inflammatory diseases and technology platforms. She currently serves as a Director on the board of Trevi Therapeutics (NASDAQ:TRVI).
Prior to joining Omega, she spent three years at MIT’s Technology Licensing Office as a licensing associate and associate licensing officer, where she managed a portfolio of drug delivery and biotechnology inventions. Annie also worked as an independent consultant for Nelsen Biomedical, where she performed market analyses and advised clients on partnering and market entry strategies. Annie earned her PhD in Biomedical Engineering from the University of Michigan and a BS in Biomedical Engineering from the University of Virginia.
Vincent joined Omega Funds in 2014 and subsequently joined NeoMed in 2017. He focuses on European investments in the areas of oncology, autoimmune and inflammatory diseases and medtech.
Previously, Vincent worked with Sectoral Asset Management, a healthcare institutional investor, as a Partner for private investments. From 2000 to 2006 he was a research fellow at the University of Geneva, studying the molecular basis of brain function, and also acted as Sectoral Asset Management’s Chief Scientific Officer during this period. Previously, he worked at Pictet Bank as a research analyst for biotechnology equities and as a co-manager of the Pictet Biotech Fund, a $2 billion listed investment vehicle. Vincent trained as a postdoctoral fellow in Geneva (Hoffman-La-Roche and Human Frontier Science Program fellow) and at the National Cancer Institute in Bethesda, MD. He completed a Certificate in International Finance and Global Markets at the Georgetown University School of Business and holds an MS in Computational Sciences, an MS in Molecular Biology, and a PhD in Molecular Biology, all from the University of Geneva.
Philipp joined Omega Funds in 2018 and assists with the accounting and financial reporting for the firm’s management company and fund vehicles.
Before joining Omega, Philipp was responsible for all operations and financial reporting at a family office. Prior to his role at the family office, he worked in public accounting at PwC, focusing primarily on alternative investment clients. Philipp received his BA in Business Administration from Furman University and holds a MSA/MBA from Northeastern University. He is also licensed as a Certified Public Accountant in the Commonwealth of Massachusetts and is a CFA Exam Level III Candidate.
Gilchrist joined Omega Funds in 2018 and assists with the accounting and financial reporting for the firm’s management company and fund vehicles.
Prior to joining Omega, Gilchrist worked in similar roles at Vista Equity Partners and Benefit Street Partners, while also having earlier experience working in public accounting at PwC. Gilchrist received both his BS in Business Administration and his MSA from the University of Rhode Island.
Mark joined Omega Funds in 2010. He manages the firm’s regulatory compliance program and assists with the firm’s financial operations and reporting.
Prior to joining Omega, Mark worked for three years as the Accounting Manager at Schooner Capital, a private investment firm in Boston. Prior to Schooner, he worked for several years in hedge fund administration at Bisys. Mark received his BS in Accounting from Plymouth State University and his MBA from Suffolk University. He is also licensed as a Certified Public Accountant in the Commonwealth of MA.
Pennylynn joined Omega Funds in 2017. She provides administrative support to Otello Stampacchia and has over nine years of experience in sales and administration. Prior to joining Omega, Pennylynn worked at Black Box Networks Services where she supported two executives, a sales team of 20, and worked as the primary lead for pricing on all high value RFPs. She also worked as an independent consultant, specialty in project management and data integrity. Pennylynn graduated Cum Laude from the University of Missouri Saint Louis and holds a BS in Business Administration.
Ellissa joined Omega Funds in 2017. She provides administrative support to Richard Lim and Michelle Doig. Prior to joining Omega, Ellissa worked as a Program Manager for the U.S. Air Force. Prior to working for the Air Force, Ellissa taught second grade for three years. Ellissa graduated Magna Cum Laude from the University of Vermont and holds a BS in Elementary Education with a concentration in Communication Sciences.
Caroline joined Omega Funds in 2019. She serves as Omega Funds’ receptionist while providing general administrative support to the team. Prior to joining Omega, Caroline worked as a teacher at The New England Center for Children where she implemented behavioral and educational programs for young adults with autism. Caroline graduated from Saint Joseph’s University in 2018 and holds a BS in Interdisciplinary Health Services with concentrations in Healthcare Ethics and Psychology.
Heather joined Omega Funds in 2018. She provides general administrative support to the investment and finance teams. Prior to joining Omega, Heather worked as a program manager at Horizons for Homeless Children helping to oversee a network of more than 1000 volunteers. Heather earned her MPA from Bridgewater State University in 2017 after completing her BA in Political Science.
Erik founded NeoMed in 1997 and served as its Managing Partner until 2015. He will continue to manage NeoMed’s funds and is available to advise on certain investments for Omega Fund V. He has over 30 years’ experience of venture capital investing in Europe and the United States, the last 20 of which have been in the healthcare industry. Previously, Erik was Chairman of NeoMed AS, an investment advisory firm specialized in the healthcare industry, and President of Origo Ventures AS, a Norwegian private equity firm. Erik is a co-founder and former chairman of the Norwegian Venture Capital Association. Erik holds a Master’s degree of Science in Management from the Graduate School of Business, Stanford University, and a PhD in Organic Chemistry from the University of Oslo, Norway.
Charles (Charlie) McDermott joined Omega Funds in January 2019. Charlie has more than 24 years of experience in the life sciences industry and has held roles of increasing responsibility in drug discovery, regulatory affairs, corporate development, commercial planning, and executive management. Charlie also currently serves as Director at Primmune Therapeutics. Previously, Charlie served as President, Chief Business Officer, and a member of the board of directors of Impact Biomedicines, Inc. Impact was acquired by Celgene in 2018 for $1.1 billion upfront and up to $7 billion overall, if all contingent payments are realized. Prior to joining Impact, Charlie was President and Chief Business Officer of Kala Pharmaceuticals, Inc. Before Joining Kala, Charlie worked at Allergan as Vice President, Global Business Development for the Eye Care and Drug Delivery business units. Before Joining Allergan, Charlie was Associate Director of Business Development at deCODE genetics and before that he worked at Pfizer/Agouron in drug discovery and regulatory affairs. Charlie has a B.A. in biochemistry and molecular biology from UC Santa Cruz, a M.A. in molecular, cellular, and developmental biology from UC Santa Barbara, and a MBA from the University of San Diego.